Curated News
By: NewsRamp Editorial Staff
May 07, 2026

NRx Pharma Gets FDA Nod for Phase 2/3 Trial of NRX-101 in Suicidal Depression

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • NRx Pharmaceuticals gains FDA clearance for Phase 2/3 trial of NRX-101, potentially leading to first-in-class treatment for suicidal depression.
  • The FDA-cleared trial will evaluate NRX-101 with TMS in 240 patients across academic, HOPE Therapeutics, and military sites.
  • This trial aims to develop new treatment options for patients with treatment-resistant depression and suicidality, offering hope.
  • NRX-101 is an oral combination of D-cycloserine and lurasidone, targeting NMDA receptors to treat suicidal depression.

Impact - Why it Matters

This trial is significant because it addresses the urgent need for effective treatments in patients with treatment-resistant major depressive disorder and suicidality, a population at high risk. If successful, NRX-101 could offer a new therapeutic option that combines oral medication with transcranial magnetic stimulation, potentially reducing suicide rates and improving quality of life. The FDA's clearance also validates NRx's NMDA platform, paving the way for further innovation in CNS disorders.

Summary

NRx Pharmaceuticals (NASDAQ: NRXP) has received FDA clearance to initiate a Phase 2/3 clinical trial for NRX-101, targeting patients with treatment-resistant major depressive disorder and suicidality. The study, conducted by subsidiary NRx Defense Systems, will enroll 240 participants across academic, HOPE Therapeutics, and military treatment facility sites. It will evaluate NRX-101 in combination with active or sham transcranial magnetic stimulation, aiming to address a critical unmet need in mental health.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on central nervous system disorders, including suicidal depression, chronic pain, and PTSD. Their pipeline includes NRX-100 (preservative-free intravenous ketamine) with Fast Track Designation for suicidal ideation in depression, and NRX-101 (oral D-cycloserine/lurasidone) with Breakthrough Therapy Designation for suicidal bipolar depression. The company has filed an Abbreviated New Drug Application and initiated a New Drug Application for NRX-100, seeking a Commissioner’s National Priority Voucher for treating suicidal ideation in depression and bipolar depression.

Investors can find the latest updates on NRXP in the company’s newsroom at https://ibn.fm/NRXP. The press release was distributed by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, offering wire-grade press release syndication and corporate communications solutions. This development underscores NRx's commitment to advancing therapies for severe mental health conditions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NRx Pharma Gets FDA Nod for Phase 2/3 Trial of NRX-101 in Suicidal Depression

blockchain registration record for this content.